Figure 1. |
Kidney Failure in the United States |
| Figure 2. |
Relationship Between Current and Previous Anemia Guidelines |
| Figure 3. |
Relationship Between Hb Level and eGFR |
| Figure 4. |
Relationship Between eGFR and Prevalence of Anemia as Defined by Differing Hb Levels for (A) Males and (B) Females |
| Figure 5. |
Prevalence of Anemia by CKD Stage |
| Figure 6. |
Relationship Between Level of Renal Function, Reflected by SCr Level or GFR, and Prevalence of Anemia, Defined at Different Hb Cutoff Levels, Among Patients under the Care of Physicians |
| Figure 7. |
Hb Percentiles by GFR in the Canadian Multicentre Longitudinal Cohort Study |
| Figure 8. |
Prevalence of Low Hb Level by Category of GFR in the Canadian Multicentre Longitudinal Cohort Study |
| Figure 9. |
Prevalence of Low Hb Level by eGFR in Patients with Diabetics Compared with the General Population |
| Figure 10. |
Changes in Hb Levels and eGFR Over 2 years in Adult Patients with CKD Stages 3 and 4 Not Treated with ESA |
| Figure 11. |
Distribution of Hb Levels in Adult Males and Females by Age Group |
| Figure 12. |
Distribution of Ferritin and TSAT Values by Age Group in Males and Females |
| Figure 13. |
Distribution of Hb Levels by Ferritin Range in Patients with CKD |
| Figure 14. |
Distribution of Hb Levels by TSAT Range in Patients with CKD |
| Figure 15. |
Target and Achieved Hb Levels in 18 RCTs Comparing Higher Against Lower (or Placebo/Control) Hb Targets for ESA Therapy |
| Figure 16. |
Baseline Mean Pretreatment Hb Levels Compared with Achieved Mean Hb Levels in the Upper and Lower Target |
| Figure 17. |
Exposure to Eprex® and Case Counts of PRCA |
| Figure 18. |
Mean Epoetin Dose per Patient per Administration by Percentile of Dose (1st, 5th to 95th, and 99th) |
| Figure 19. |
Process of Triaging a Topic to a Systematic Review or a Narrative Review |